RENOVARO CUBE

Renovaro Cube is commited to the early detection of cancer, to intervene at a stage where treatment can be most effective. We are pioneering a multi-modal approach for the early detection of cancer and its recurrence involving blood biopsies, imaging and multi-omics analysis.

For more information on Renovaro Cube, go to their website at renovarocube.com

RENOVARO BIO

Renovaro Biosciences, Inc. has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases.

For more information on Renovaro Biosciences, go to their website at renovarobio.com

News Items

All News Items
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy

May 24, 2024

Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy

This collaboration would bring together Renovaro’s proprietary cancer vaccine technology and the Cancer Center’s expertise in several ancillary immunomodulatory technologies, towards innovative advancements in cancer treatment.

Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

April 30, 2024

Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

Avram Miller Talks About Renovaro And Its Impact In Diagnosing Cancers and Infectious Diseases With AI

April 29, 2024

Avram Miller Talks About Renovaro And Its Impact In Diagnosing Cancers and Infectious Diseases With AI

The potential impact of AI on healthcare is vast and transformative. With the use of AI platforms for diagnosing diseases like cancer, we can expect improved accuracy, efficiency, and outcomes in patient care. Renovaro stands at the forefront of this innovative shift towards a more intelligent healthcare system powered by artificial intelligence.

RenovaroCube to Acquire 100% Ownership of Cyclomics

April 24, 2024

RenovaroCube to Acquire 100% Ownership of Cyclomics

RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment.

Button

Information request form

Your inquiries matter. Feel free to use the form below to get in touch, and our team will make it a priority to respond as quickly as possible.

man sight on white microscope
a future free from toxic chemotherapy